629 related articles for article (PubMed ID: 23141052)
1. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
2. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions.
Komatsu-Fujii T; Kaneko S; Chinuki Y; Suyama Y; Ohta M; Niihara H; Morita E
Allergol Int; 2017 Jan; 66(1):116-122. PubMed ID: 27497618
[TBL] [Abstract][Full Text] [Related]
3. Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10.
Wang F; He D; Tang X; Zhang X
Ann Allergy Asthma Immunol; 2014 Aug; 113(2):204-8. PubMed ID: 24932689
[TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
5. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation.
Komatsu-Fujii T; Chinuki Y; Niihara H; Hayashida K; Ohta M; Okazaki R; Kaneko S; Morita E
Allergol Int; 2018 Jan; 67(1):90-95. PubMed ID: 28648978
[TBL] [Abstract][Full Text] [Related]
6. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.
Kakinuma T; Nakamura K; Wakugawa M; Mitsui H; Tada Y; Saeki H; Torii H; Asahina A; Onai N; Matsushima K; Tamaki K
J Allergy Clin Immunol; 2001 Mar; 107(3):535-41. PubMed ID: 11240957
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
[TBL] [Abstract][Full Text] [Related]
8. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
[TBL] [Abstract][Full Text] [Related]
9. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
10. Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities.
Miyagawa F; Hasegawa A; Imoto K; Ogawa K; Kobayashi N; Ito K; Fujita H; Aihara M; Watanabe H; Sueki H; Tohyama M; Asada H
Eur J Dermatol; 2015; 25(1):87-9. PubMed ID: 25547780
[No Abstract] [Full Text] [Related]
11. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS).
Ogawa K; Morito H; Hasegawa A; Miyagawa F; Kobayashi N; Watanabe H; Sueki H; Tohyama M; Hashimoto K; Kano Y; Shiohara T; Ito K; Fujita H; Aihara M; Asada H
Br J Dermatol; 2014 Aug; 171(2):425-7. PubMed ID: 24601914
[No Abstract] [Full Text] [Related]
14. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
15. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity.
Hanafusa T; Azukizawa H; Matsumura S; Katayama I
J Dermatol Sci; 2012 Mar; 65(3):213-9. PubMed ID: 22226608
[TBL] [Abstract][Full Text] [Related]
16. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
[TBL] [Abstract][Full Text] [Related]
17. Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms.
Morito H; Ogawa K; Fukumoto T; Kobayashi N; Morii T; Kasai T; Nonomura A; Kishimoto T; Asada H
Clin Exp Dermatol; 2014 Apr; 39(3):284-91. PubMed ID: 24635062
[TBL] [Abstract][Full Text] [Related]
18. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia.
Miyazaki E; Nureki S; Fukami T; Shigenaga T; Ando M; Ito K; Ando H; Sugisaki K; Kumamoto T; Tsuda T
Am J Respir Crit Care Med; 2002 Apr; 165(8):1125-31. PubMed ID: 11956056
[TBL] [Abstract][Full Text] [Related]
20. T cell populations propagating in the peripheral blood of patients with drug eruptions.
Nishio D; Izu K; Kabashima K; Tokura Y
J Dermatol Sci; 2007 Oct; 48(1):25-33. PubMed ID: 17601705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
